Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: Late presenters vs. late starters

HIV Medicine

Volumn 12, Issue 5, 2011, Pages 289-298

  Waters, L ^a   Fisher, M ^b   Anderson, J ^c   Wood, C ^d   Delpech, V ^e   Hill, T ^f   Walsh, J ^g   Orkin, C ^h   Bansi, L ^f   Gompels, M ⁱ   Phillips, A ^f   Johnson, M ^f   Gilson, R ^f   Easterbrook, P ^j   Leen, C ^k   Porter, K ^l   Gazzard, B ^a   Sabin, C ^f  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Worthing Hospital   (United Kingdom)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g ST MARY S HOSPITAL   (United Kingdom)

^h BARTS HEALTH NHS TRUST   (United Kingdom)

ⁱ NORTH BRISTOL NHS TRUST   (United Kingdom)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

^k NHS LOTHIAN   (United Kingdom)

^l MEDICAL RESEARCH COUNCIL   (United Kingdom)

more..

Author keywords

Highly active antiretroviral therapy outcomes; HIV; Late presenters; UK CHIC

Indexed keywords

ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; VIRUS SUPPRESSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; RISK FACTORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79953269806     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00881.x     Document Type: Article

References (19)

1. Egger M, May M, Chêne G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
2. El-Sadr WM, Grund B, Neuhaus J et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149: 289-299.
3. Uy J, Armon C, Buchacz K et al. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009; 51: 450-453.
4. Ellis R, Heaton R, Letendre S et al. Higher CD4 Nadir Is Associated with Reduced Rates of HIV-associated Neurocognitive Disorders in the CHARTER Study: Potential Implications for Early Treatment Initiation. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract 429].
5. Moore RD, Keruly JC. CD4+cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44: 441-446.
6. Le Moing V, Thiébaut R, Chêne G et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently<500 copies/mL during treatment with antiretroviral drugs. HIV Med 2007; 8: 156-163.
7. Kelley CF, Kitchen CM, Hunt PW et al. Incomplete peripheral CD4+cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48: 787-794.
8. HPA data. HIV in the United Kingdom: 2009 Report. Available at (accessed 1 June 2010).
9. Egger M. Outcomes of ART in Resource-limited and Industrialized Countries. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 62].
10. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46 (Suppl 1): S3-S8.
11. Sabin CA, Smith CJ, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18: 2145-2151.
12. Wolbers M, Bucher HC, Furrer H et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 2008; 9: 397-405.
13. British HIV Association Audit and Standards Subcommittee: Mortality audit. London, UK: British HIV Association, 2006. Available at (accessed 8 July 2008).
14. Chadborn T, Delpech V, Sabin C, Sinka K, Evans B. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20: 2371-2379.
15. Hughes R, Sabin C, Sterne J. Long-term Trends in CD4 Count in Patients Starting HAART: UK-CHIC Study. 11th European AIDS Conference. Madrid, Spain, October 2007 [Abstract P18.4/04].
16. Baker JV, Peng G, Rapkin J et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48: 541-546.
17. Stohr W, Dunn DT, Porter K et al. CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Med 2007; 8: 135-141.
18. Harte D, Dosekun O, Sethi G et al. Immunosuppression among HIV-1-positive patients attending for care: experience from two large HIV centres in the United Kingdom. HIV Med 2010; 11: 114-120.
19. Gompels M, Sabin C, Phillips A, Dunn D. The Frequency and Clinical Implications of a Discordant CD4 Count and CD4 Percentage. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 343].